Catch up on the top radiology content of the past week.
|Articles|May 8, 1996
SMV reorganizes upper management
Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for
Advertisement
Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for SMVAmerica and SMV International.
SMV spokesperson Robert Ripley said that Debionne's positionwas a transitional one designed to help smooth the integrationof SMV's predecessors, Sopha and Summit Nuclear, while McNaughtdeparted for personal reasons. McNaught previously was head ofSopha's U.S. unit.
Neither McNaught nor Debionne will be replaced, according toRipley. SMV International chief executive Jean Plazenet will assumethe responsibilities of both executives. Summit veteran RandallSommerdyke remains president of SMV America, Ripley said.
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5